Paul N. Durfee

TL;DR: P porous nanoparticle-supported lipid bilayers (protocells) that synergistically combine properties of liposomes and nanoporous particles are reported that allow a single protocell loaded with a drug cocktail to kill a drug-resistant HCC cell, representing a 106-fold improvement over comparable liposome.

TL;DR: The results demonstrate that MS2 VLPs, because of their tolerance of multivalent peptide display and their ability to specifically encapsidate a variety of chemically disparate cargos, induce selective cytotoxicity of cancer in vitro and represent a significant improvement in the characteristics of VLP-based delivery systems.

TL;DR: Overall, the effectiveness of the protocell platform for individual cell targeting and delivery needed for leukemia and other disseminated disease is established.

TL;DR: It is shown that increased particle size results in a monotonic decrease in systemic bioavailability, irrespective of route of administration, with corresponding accumulation in liver and spleen, and important predictive functional correlations are provided to support the rational design of nanomedicines.